To test the use of these changes for predicting future relapses, we divided the trial participants into groups, those with increasing and those with decreasing TNF+ naïve or IgM‐only MBC frequencies between day 1 and day 60, and compared their time before conversion from CIS to MS (Figure 6b and c). The gene discussed is CD40LG; the disease is in situ carcinoma.